The acute effects of different spironolactone doses on cardiac function in streptozotocin-induced diabetic rats

Can J Physiol Pharmacol. 2017 Nov;95(11):1343-1350. doi: 10.1139/cjpp-2017-0055. Epub 2017 Jul 26.

Abstract

Currently, cardiovascular diseases are the leading cause of global mortality, while diabetes mellitus remains an important cause of cardiovascular morbidity. A recent study showed that patients with diabetes mellitus treated with mineralocorticoid receptor antagonists have improved coronary microvascular function, leading to improved diastolic dysfunction. In this study, we evaluated the influence of acute administration of spironolactone on myocardial function in rats with streptozotocin-induced diabetes mellitus, with special emphasis on cardiodynamic parameters in diabetic rat hearts. The present study was carried out on 40 adult male Wistar albino rats (8 weeks old). Rats were randomly divided into 4 groups (10 animals per group): healthy rats treated with 0.1 μmol/L of spironolactone, diabetic rats treated with 0.1 μmol/L of spironolactone, healthy rats treated with 3 μmol/L of spironolactone, and diabetic rats treated with 3 μmol/L of spironolactone. Different, dose-dependent, acute responses of spironolactone treatment on isolated, working diabetic and healthy rat heart were observed in our study. In healthy rats, better systolic function was achieved with higher spironolactone dose, while in diabetic rats, similar effects of low and high spironolactone dose were observed.

Keywords: cardiodynamics; cardiodynamie; cœur isolé; isolated heart; oxidative parameter; paramètre de l’oxydation; rat; spironolactone; streptozotocin; streptozotocine.

MeSH terms

  • Animals
  • Coronary Circulation / drug effects
  • Diabetes Mellitus, Experimental / physiopathology*
  • Dose-Response Relationship, Drug
  • Heart / drug effects*
  • Heart / physiopathology*
  • Heart Rate / drug effects
  • Male
  • Rats
  • Rats, Wistar
  • Spironolactone / pharmacology*
  • Spironolactone / therapeutic use
  • Ventricular Dysfunction, Left / drug therapy

Substances

  • Spironolactone